Prevalence of Metabolic Syndrome and Its Parameters and Their Correlations With Psoriasis Duration, Severity, and Sleep Quality In Psoriasis Patients: A Cross-Sectional Study
Keywords:
psoriasis, metabolic syndrome, sleep quality, comorbidityAbstract
Background: Psoriasis is an inflammatory skin disease that may lead to comorbidities, including metabolic syndrome (MS).
Objective: We determined the prevalence of MS and its correlation with psoriasis duration, severity, and sleep quality in psoriasis patients.
Methods: A total of 112 subjects with chronic plaque psoriasis were studied. Demographics, MS parameters, disease duration, severity, and sleep quality were examined. The Psoriasis Area and Severity Index (PASI)and the Pittsburgh Sleep Quality Index (PSQI) were used to assess psoriasis severity and sleep quality, respectively. Presence of MS and its correlations with psoriasis duration, severity and sleep quality were investigated.
Results: Of 112 patients, 76 (67.8%) were diagnosed with MS. Of all patients, 74.1% had a high PASI, and 84.8% had a high PSQI. The mean values of psoriasis duration, body mass index, waist circumference, fasting glucose, HOMA-IR, triglyceride levels, blood pressure, PSQI, sleep latency, and daytime sleep dysfunction were significantly higher in the MS group than non-MS group, whereas the mean HDL level was lower. The prevalences of MS, high fasting glucose, and low HDL were significantly higher among female, but not male, patients with severe psoriasis (PASI >10) than those without severe psoriasis. Disease duration, high body mass index, waist circumference, blood pressure, fasting glucose, HOMA-IR, triglyceride levels, low HDL, and poor sleep quality were significantly correlated with the presence of MS. However, only waist circumference, fasting glucose, blood pressure, and low HDL were predictive of the development of MS.
Conclusions: MS is common among psoriasis patients, and especially in females with advanced psoriasis, high fasting glucose, and low HDL levels. Besides diagnostic criteria of MS, a long duration of psoriasis, poor sleep quality and high-HOMA-IR correlate with the development of MS. High fasting glucose and low HDL levels may facilitate MS development in association with psoriasis severity in females.
References
Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29(1):10-15. DOI: 10.1016/j.sder.2010.01.002. PMID: 20430302.
Lotti T, Hercogova J, Prignano F. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? Dermatol Ther. 2010;23(2):119-122. DOI: 10.1111/j.1529-8019.2010.01305.x. PMID: 20415818.
Altunay I, TukenmezDemirci G, Ates B, et al. Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study. Clin CosmetInvestig Dermatol.2011;4:139-143. DOI: 10.2147/CCID.S24165. PMID: 21931499.
Herron MD, Hincley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527-1533. DOI:10.1001/archderm.141.12.1527. PMID: 16365253.
Sterry W, Strober BE, Menter A; International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol.2007;157(4):649-655. DOI: 10.1111/j.1365-2133.2007.08068.x. PMID: 17627791.
Hamminga EA, van der Lely AJ, Neumann HA,Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768-773. DOI: 10.1016/j.mehy.2005.11.050. PMID: 16781085.
Bonifati C, Carducci M, CordialiFei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocytecolony stimulating factor levels in suction blister fluids and sera of psoriatic patients—relationships with disease severity. Clin Exp Dermatol. 1994;19(5):383-387. DOI: 10.1111/j.1365-2230.1994.tb02687.x.
Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin. 2004;20(3):295-304. DOI: 10.1185/030079903125003008. PMID: 15025838.
Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785-1796. DOI: 10.1038/jid.2010.103. PMID: 20445552.
Lam JCM, Mak JCW, Ip MSM. Obesity, obstructive sleep apnoea and metabolic syndrome. Respirology. 2010;17(2):223-236. DOI: 10.1111/j.1440-1843.2011.02081.x. PMID: 21992649.
Hawro T, Hawro M, Zalewska-Janowska A, Weller K, Metz M, Maurer M. Pruritus and sleep disturbances in patients with psoriasis. Arch Dermatol Res. 2020;312(2):103-111. DOI:10.1007/s00403-019-01998-7. PMID: 31616971.
Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl2):65-68. DOI: 10.1136/ard.2004.031237. PMID: 15708941.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res.1989;28(2):193-213. DOI: 10.1016/0165-1781(89)90047-4. PMID: 2748771.
Agargun MY, Kara H, Anlar O. [The validity and reliability of the Pittsburgh Sleep Quality Index.] Abstract in English.TurkPsikiyatriDerg. 1996;7(2):107-115.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. DOI: 10.1001/jama.285.19.2486. PMID: 11368702.
WHO Expert Consultation.Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.Lancet.2004;363(9403):157-163. DOI: 10.1016/S0140-6736(03)15268-3. PMID: 14726171.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894:i-xii, 1-253. PMID: 11234459.
Alderman MH. JNC 7: brief summary and critique. Clin Exp Hypertens.2004;26(7-8):753-761. DOI: 10.1081/ceh-200032158. PMID: 15702631.
Matthews DR, Hosker JK, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. DOI: 10.1007/BF00280883. PMID: 3899825.
Singh Y, Garg MK, Tandon N, Marwaha RK. A Study of insulin resistance by HOMA-IR and its cut-off value to identify metabolic syndrome in urban Indian adolescents. J Clin Res Pediatr Endocrinol. 2013;5(4):245-251. DOI: 10.4274/Jcrpe.1127. PMID: 24379034.
Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. DOI: 10.1371/journal.pone.0181039. PMID: 28719618.
Yayli S, Topbas M, Aksu Arica D, et al. The prevalence of psoriasis in Trabzon. Turkderm. 2016;50(4):141-144. DOI: 10.4274/turkderm.75735.
Gundogan K, Bayram F, Capak M, et al. Prevalence of metabolic syndrome in the world and Turkey.TurkiyeKlinikleri J Int Med Sci.2006;2:18-24.
Gemalmaz A, Aydin S, Basak O, Discigil G, Kurul A. Prevalence of metabolic syndrome in a rural Turkish population: Comparison and concordance of two diagnostic criteria. Turk J Med Sci.2008;38(2):159-165.https://app.trdizin.gov.tr/publication/paper/detail/TnpnNE5UVTE=
Ferdinando LB, Fukumoto PK, Sanches S, Fabricio LHZ, Skare TL. Metabolic syndrome and psoriasis: a study in 97 patients. Rev Assoc Med Bras. 2018;64(4):368-373. DOI: 10.1590/1806-9282.64.04.368. PMID: 30133617.
Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasisandthemetabolicsyndrome. ClinDermatol. 2018;36(1):21-28. DOI:10.1016/j.clindermatol.2017.09.005. PMID: 29241748.
Zindanci I, Albayrak O, Kavala M, et al. Prevalence of metabolic syndrome in patients with psoriasis. The scientific world journal. 2012;2012:312463. DOI:10.1100/2012/312463. PMID:22654590.
Tasliyurt T, Bilir Y, Sahin S, et al. Erectile dysfunction in patients with psoriasis: potential impact of the metabolic syndrome. Eur Rev Med Pharmacol Sci. 2014;18(4):581–586. PMID: 24610625
Adişen E, Uzun S, Erduran F, Gürer MA. Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. An Bras Dermatol. 2018;93(2):205-211. DOI: 10.1590/abd1806-4841.20186168. PMID: 29723384.
Baeta IG, Bittencourt FV, Gontijo B, Marcos E, Goulart A. Comorbidities and cardiovascular risk factors in patients with psoriasis. An Bras Dermatol. 2014;89(5):735-744. DOI:10.1590/abd1806-4841.20142874. PMID: 25184912.
Balkan F. Metabolic syndrome.Article in Turkish. Ankara Med J.2013;13:85-90. https://dergipark.org.tr/tr/pub/amj/issue/1739/21396
Kim GW, Park HJ, Kim HS, et al. Analysis of cardiovascular risk factors and metabolic syndrome in Korean patients with psoriasis. Ann Dermatol.2012;24(1):11-15. DOI: 10.5021/ad.2012.24.1.11. PMID: 22363149.
Itani S, Arabi A, Harb D, Hamzeh D, Kıbbi AG. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol.2016;55(4):390-395. DOI: 10.1111/ijd.12811. PMID: 26748974.
Polic MV, Miskulin M, Smolic M, et al. Psoriasis severity-a risk factor of insulin resistance independent of metabolic syndrome. Int J Environ Res Public Health. 2018 13;15(7):1486. DOI: 10.3390/ijerph15071486. PMID: 3001841.
Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CEM, Bundy C. Measurement, classification and evaluation of sleep disturbance in psoriasis: a systematic review. PLoS One. 2016;21;11(6):e0157843. DOI: 10.1371/journal.pone.0157843. PMID: 27327082.
Hawro T, Hawro M, Zalewska-Janowska A, Weller K, Metz M, Maurer M. Pruritus and sleep disturbances in patients with psoriasis. Arch Dermatol Res.2019;312(2):103-111. DOI: 10.1007/s00403-019-01998-7.PMID: 3131671.
Biçici F, Hayta SB, Akyol M, Özçelik S, Çınar Z. Evaluation of sleep quality in patients with psoriasis. Turkderm. 2015;49(3):208-212. DOI: 10.4274/turkderm.70707
Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010;63(1):114-123. DOI: 10.1016/j.jaad.2009.07.003. PMID: 19944485.
Melikoglu M. Sleep quality and its association with disease severity in psoriasis. Eurasian J Med.2017;49:124-127. DOI: 10.5152/eurasianjmed.2017.17132. PMID: 28638255.
Jensen P, Zachariae C, Skov L, Zachariae R. Sleep disturbance in psoriasis—a case-controlled study. Br J Dermatol. 2018;179(6):1376-1384. DOI: 10.1111/bjd.16702. PMID: 29704428.
Shutty BG, West C, Huang KE, et al. Sleep disturbances in psoriasis. Dermatol Online J. 2013;19(1)1. PMID: 23374943.
Stinco G, Trevisan G, Piccirillo F, et al. Psoriasis vulgaris does not adversely influence the quality of sleep. G Ital Dermatol Venerol. 2013;148(6):655-659. PMID: 24442047.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
